We envision a future where cancer is no longer a grim diagnosis because treatments exist that eliminate it at the source, and cures come without the severe systemic side effects of current-day immuno-oncology therapies.
We are using our proprietary platform to design and deliver tumor-activated immuno-oncology therapies that provide effective, tolerable, and durable therapeutics options for patients with solid tumors. We are building a pipeline of novel, tumor-activated molecules, including antibodies, cytokines and other biologics, that are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment without systemic effect. Click on the links below to learn more:
What tumor-activated immunotherapy could mean for people with cancer
Chrissy was a chef and mother of two, who was diagnosed with lung cancer and passed away in July 2021 after a long and courageous battle. She was committed to treating the disease aggressively, but her therapies caused severe side effects, including severe dehydration, swelling, vascular leak syndrome, fatigue, dizziness, mouth sores, back pain, and heartburn. Minimizing toxicity with a tumor-activated approach could allow for more effective anti-tumor treatment without debilitating adverse events for patients like Chrissy in the future.